Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
Enlighten Festival held in Canberra, AustraliaChina endeavors to build characteristic townsXi to Travel to U.S. for ChinaMore international flights for summer seasonChina hosts 135th Canton Fair in GuangzhouConsumer expo to display more new itemsColorful lights and lanterns light up to celebrate upcoming Lunar New Year in SingaporePalestinian artist reveals violence against women in Gaza through paintingsFamily in NW China's Ningxia carries forward paper cutting cultureIntangible cultural heritages brings new color to Fujian's night economy